These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35172062)

  • 21. Rehospitalization, Emergency Visits After Paxlovid Treatment Are Rare.
    Kuehn BM
    JAMA; 2022 Jul; 328(4):323. PubMed ID: 35881113
    [No Abstract]   [Full Text] [Related]  

  • 22. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19.
    Shah MM; Joyce B; Plumb ID; Sahakian S; Feldstein LR; Barkley E; Paccione M; Deckert J; Sandmann D; Hagen MB; Gerhart JL
    Clin Infect Dis; 2024 Jul; 79(1):108-110. PubMed ID: 38411622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delayed treatment with nirmatrelvir/ritonavir could remain effective in patients with Omicron BA2.2 variant of COVID-19.
    Wang W; Wan J; Du W; Song J; Lu Y; Gu S; Feng Y; Wang G; Tao M; Yin J
    Ann Acad Med Singap; 2023 Mar; 52(3):158-160. PubMed ID: 38904494
    [No Abstract]   [Full Text] [Related]  

  • 25. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19.
    Chang LC; Chen IW; Hung KC
    J Med Virol; 2024 Feb; 96(2):e29464. PubMed ID: 38329167
    [No Abstract]   [Full Text] [Related]  

  • 27. Audio Interview: Addressing the Omicron Variant of SARS-CoV-2.
    Rubin EJ; Baden LR; Barocas JA; Morrissey S
    N Engl J Med; 2022 Jan; 386(4):e16. PubMed ID: 35081288
    [No Abstract]   [Full Text] [Related]  

  • 28. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
    Azanza JR; Mensa J; González Del Castillo J; Linares Rufo M; Molero JM; Madero Valle N; Barberán J
    Rev Esp Quimioter; 2022 Aug; 35(4):357-361. PubMed ID: 35822605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paxlovid Is Effective but Underused-Here's What the Latest Research Says About Rebound and More.
    Rubin R
    JAMA; 2024 Feb; 331(7):548-551. PubMed ID: 38294771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Covid-19: What is the evidence for the antiviral Paxlovid?
    Extance A
    BMJ; 2022 Apr; 377():o1037. PubMed ID: 35477536
    [No Abstract]   [Full Text] [Related]  

  • 31. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Audio Interview: How Much Protection Does Prior SARS-CoV-2 Infection Provide?
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(25):e100. PubMed ID: 34910868
    [No Abstract]   [Full Text] [Related]  

  • 33. Audio Interview: Waning Immunity against SARS-CoV-2.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(24):e99. PubMed ID: 34879456
    [No Abstract]   [Full Text] [Related]  

  • 34. Comment on "Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19".
    Lin YL; Yu CH; Wei JC
    Int J Antimicrob Agents; 2024 Feb; 63(2):107063. PubMed ID: 38103754
    [No Abstract]   [Full Text] [Related]  

  • 35. COVID-19 update: Prescription of Paxlovid by pharmacists.
    Med Lett Drugs Ther; 2022 Aug; 64(1656):e124. PubMed ID: 35921075
    [No Abstract]   [Full Text] [Related]  

  • 36. Audio Interview: Covid-19 Vaccination and the Omicron Variant.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(27):e102. PubMed ID: 34965346
    [No Abstract]   [Full Text] [Related]  

  • 37. Audio Interview: Can We Make More Effective Covid-19 Vaccines?
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2022 Mar; 386(11):e36. PubMed ID: 35294821
    [No Abstract]   [Full Text] [Related]  

  • 38. Audio Interview: What's Gone Right in Our Battle against Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Nov; 385(22):e95. PubMed ID: 34818488
    [No Abstract]   [Full Text] [Related]  

  • 39. Correspondence on 'Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series'.
    Zhou XX; Ji HJ
    Eur J Hosp Pharm; 2024 Feb; 31(2):178-179. PubMed ID: 36737228
    [No Abstract]   [Full Text] [Related]  

  • 40. COVID-19: LMICs need antivirals as well as vaccines.
    Bajaj SS; Stanford FC
    Nature; 2022 Feb; 602(7895):33. PubMed ID: 35105995
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.